How should I evaluate and manage prostatitis (acute bacterial prostatitis, chronic bacterial prostatitis, chronic prostatitis/chronic pelvic pain syndrome, or asymptomatic inflammatory prostatitis) in a male patient presenting with pelvic, perineal or low‑back pain, dysuria, urinary frequency, urgency, painful ejaculation, or fever?

Evaluation and Management of Prostatitis

Initial Classification and Diagnostic Approach

Begin by classifying the patient into one of four categories based on clinical presentation and simple laboratory tests: acute bacterial prostatitis (NIH Category I), chronic bacterial prostatitis (NIH Category II), chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS, NIH Category III), or asymptomatic inflammatory prostatitis (NIH Category IV). 1, 2

Acute Bacterial Prostatitis (Category I)

Clinical presentation includes severe genitourinary pain (perineal, suprapubic, lower back, rectal, testicular, or penile tip), fever, chills, dysuria, urinary frequency, and urgency. 1

On digital rectal examination, perform only a gentle examination—avoid vigorous prostatic massage or aggressive palpation because this can precipitate bacteremia and sepsis. 1, 3

Essential diagnostic tests include:

• Midstream urine dipstick for nitrites and leukocytes 1
• Midstream urine culture to identify causative organisms 1, 3
• Blood cultures in febrile patients 1, 3
• Complete blood count to assess for leukocytosis 1, 3
• Transrectal ultrasound only in selected cases if prostatic abscess is suspected 1, 3

Chronic Bacterial Prostatitis (Category II)

Patients present with persistent or recurrent urinary tract infections from the same bacterial strain, accompanied by pelvic pain (perineum, suprapubic area, lower back, testicles, or penile tip) and voiding symptoms (frequency, urgency, dysuria, incomplete emptying). 1

The Meares-Stamey 4-glass test is the gold standard for diagnosis: collect first-void urine, midstream urine, expressed prostatic secretions (EPS), and post-massage urine. 4, 1 A positive result shows a 10-fold higher bacterial count in the EPS compared to midstream urine. 4, 1 A simplified 2-specimen variant (midstream urine and EPS only) can be used. 4, 1

In men younger than 35 years, test for atypical pathogens including Chlamydia trachomatis and Mycoplasma species because these require specific antimicrobial therapy. 1, 3

Chronic Prostatitis/Chronic Pelvic Pain Syndrome (Category III)

CP/CPPS is diagnosed when pelvic pain or discomfort persists for at least 3 of the preceding 6 months, accompanied by urinary symptoms (frequency, urgency, incomplete emptying), without documented uropathogenic infection. 1, 2

This syndrome is not caused by a culturable infectious agent and requires different management focused on symptom relief rather than antimicrobials. 4, 1 Many patients describe "pressure" or "discomfort" rather than overt pain and may deny pain when directly questioned. 1

Pain typically intensifies after certain foods or beverages and with bladder filling, while voiding may provide relief. 1 Sexual dysfunction, including painful ejaculation and reduced libido, is frequently reported. 1

Consider overlap with interstitial cystitis/bladder pain syndrome (IC/BPS) in men with bladder-centered pain; some patients fulfill criteria for both conditions. 1

---

Treatment of Acute Bacterial Prostatitis

Antibiotic Selection Based on Severity

For severe cases requiring hospitalization (unable to tolerate oral medications, systemic toxicity, risk of urosepsis), initiate intravenous broad-spectrum antibiotics: ceftriaxone 1-2 g IV daily plus doxycycline 100 mg orally twice daily, or piperacillin-tazobactam. 3, 2

For mild-to-moderate outpatient cases, prescribe oral ciprofloxacin 500-750 mg twice daily for 2-4 weeks if local fluoroquinolone resistance is less than 10%. 1, 3, 2 This achieves a 92-97% success rate. 2

Avoid fluoroquinolones if:

• Local resistance exceeds 10% 1, 3
• The patient has received fluoroquinolones in the last 6 months 1, 3
• The patient is from a urology department (higher resistance risk) 3

Avoid amoxicillin or ampicillin empirically due to very high worldwide resistance rates (75% median E. coli resistance, range 45-100%). 1, 3

Avoid trimethoprim-sulfamethoxazole empirically unless the organism is known to be susceptible, as resistance rates are high. 1

Special Considerations for Young Men (<35 Years)

In men younger than 35 years, add doxycycline 100 mg orally twice daily for 7 days to the standard fluoroquinolone regimen to cover Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma species. 1, 3 Alternatively, azithromycin 1 g orally as a single dose can be used for Mycoplasma coverage. 1

Treatment Duration and Follow-Up

Complete a minimum of 2-4 weeks of antibiotic therapy for acute bacterial prostatitis. 1, 3, 2 Assess clinical response after 48-72 hours of treatment. 1 Stopping antibiotics prematurely can lead to chronic bacterial prostatitis, so complete the full treatment course. 1

Hospitalization Criteria

Hospitalize patients who:

• Cannot tolerate oral medications 1, 3
• Show signs of systemic toxicity or risk of urosepsis (occurs in 7.3% of cases) 1
• Have suspected prostatic abscess 1, 3

---

Treatment of Chronic Bacterial Prostatitis

First-line therapy is a minimum 4-week course of oral fluoroquinolones: levofloxacin or ciprofloxacin 500-750 mg twice daily. 2 However, 4-12 weeks of treatment is required to prevent relapse. 1

The same fluoroquinolone precautions apply as for acute prostatitis (avoid if local resistance >10% or recent use within 6 months). 1, 3

In men younger than 35 years, add doxycycline 100 mg orally twice daily for 7 days or azithromycin 1 g orally as a single dose to cover atypical pathogens. 1

Treat sexual partners while maintaining patient confidentiality in cases of sexually transmitted infections. 3 All sexual partners within the preceding 60 days should be referred for evaluation and treatment to prevent reinfection. 1 Patients should abstain from sexual activity until at least 7 days after initiating antimicrobial therapy, provided symptoms have resolved and all recent partners have been treated. 1

---

Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

First-Line Therapy: Alpha-Blockers

For CP/CPPS with urinary symptoms, prescribe alpha-blockers as first-line therapy: tamsulosin, alfuzosin, doxazosin, or terazosin are equally effective. 3, 2 These reduce the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) score by 4.8 to 10.8 points compared to placebo (a 6-point change is clinically meaningful). 3, 2

Common adverse effects include orthostatic hypotension, dizziness, tiredness, ejaculatory problems, and nasal congestion. 3 Tamsulosin has a lower risk of orthostatic hypotension but a higher risk of ejaculatory dysfunction compared to other alpha-blockers. 3

Adjunctive Therapies

Anti-inflammatory drugs (e.g., ibuprofen) reduce NIH-CPSI score by 1.7 to 2.5 points compared to placebo. 2

Pregabalin reduces NIH-CPSI score by 2.4 points compared to placebo. 2

Pollen extract reduces NIH-CPSI score by 2.49 points compared to placebo. 2

Non-Pharmacologic Approaches

Consider non-prostate-centered treatment strategies such as physical therapy, myofascial trigger point release, and relaxation techniques, particularly when symptoms suggest a neuromuscular disorder or pain syndrome. 5

What NOT to Use

Do not use 5-alpha reductase inhibitors (finasteride or dutasteride) for CP/CPPS; they are only effective for benign prostatic hyperplasia with demonstrable prostatic enlargement. 3

Do not use antibiotics for CP/CPPS unless atypical pathogens are documented, as this syndrome is not caused by a culturable infectious agent. 4, 1

---

Common Pitfalls and Caveats

Avoid vigorous prostatic massage in acute bacterial prostatitis—this is the most critical safety consideration. 1, 3 Even gentle digital rectal examination should be performed cautiously. 1

Do not assume all prostatitis is bacterial; 90-95% of prostatitis cases are CP/CPPS (Category III), which does not respond to antibiotics. 5, 6 Fewer than 10% of prostatitis cases are confirmed bacterial infections. 1, 3

In men younger than 35 years, maintain a high index of suspicion for sexually transmitted pathogens (Chlamydia, Neisseria gonorrhoeae, Mycoplasma) and incorporate appropriate testing and antimicrobial coverage. 1, 3

Local antimicrobial resistance patterns must guide empiric therapy selection. 3 Fluoroquinolones should not be used empirically if local resistance exceeds 10%. 1, 3

Re-exposure to an untreated partner is a common cause of recurrent urethritis and subsequent prostatitis; partner treatment is essential to break this cycle. 1

Up to 20% of patients with acute pyelonephritis lack bladder symptoms, and a similar pattern can occur with acute bacterial prostatitis, making diagnosis more challenging in the absence of classic lower urinary tract complaints. 1

Suprapubic pain or tenderness can accompany bladder involvement in acute bacterial prostatitis, potentially mimicking cystitis or pyelonephritis. 1